KRAS and colorectal cancer: While not much is known about the invasive gene expression subtype in colorectal cancer, clinical studies of the CpG Island Methylator Phenotype-Low (CIMP-L) subtype show that patients with this gene expression profile exhibit more KRAS mutations and show better prognosis than patients with the CIMP-high (CIMP-H) subtype [57,58].